Saltar al contenido
Merck

AB5336P

Anti-α-Synuclein (SNCA) Antibody

CHEMICON®, sheep polyclonal

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
polyclonal
Species reactivity:
rat, mouse, human
Application:
IHC
Citations:
8
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Anti-Synuclein α Antibody, Chemicon®, from sheep

biological source

sheep

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

rat, mouse, human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable (paraffin)

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... SNCA(6622)

¿Está buscando productos similares? Visita Guía de comparación de productos

Immunogen

Synthetic peptide corresponding amino acids 108-120 of human alpha synuclein.

Application

Anti-Synuclein Antibody, α is an antibody against Synuclein for use in IH(P).
Immunohistochemistry: 1:1,000 on frozen or paraffin sections.

Optimal working dilutions must be determined by the end user.

Physical form

Affinity purified immunoglobulin. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.

Other Notes

Replaces: 04-1053

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

hcodes

Hazard Classifications

Aquatic Chronic 3

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Mohamed-Bilal Fares et al.
Proceedings of the National Academy of Sciences of the United States of America, 113(7), E912-E921 (2016-02-04)
Lewy bodies (LBs) are intraneuronal inclusions consisting primarily of fibrillized human α-synuclein (hα-Syn) protein, which represent the major pathological hallmark of Parkinson's disease (PD). Although doubling hα-Syn expression provokes LB pathology in humans, hα-Syn overexpression does not trigger the formation
Avik Roy et al.
Scientific reports, 6, 22067-22067 (2016-02-27)
Ankyrin-rich BTB/POZ domain containing protein-2 or BPOZ-2, a scaffold protein, has been recently shown to control the degradation of many biological proteins ranging from embryonic development to tumor progression. However, its role in the process of neuronal diseases has not
Ayse Ulusoy et al.
The European journal of neuroscience, 32(3), 409-422 (2010-08-14)
Lewy bodies, which are a pathological hallmark of Parkinson's disease, contain insoluble polymers of alpha-synuclein (alphasyn). Among the different modifications that can promote the formation of toxic alphasyn species, C-terminal truncation is among the most abundant alterations in patients with
Martial Kamdem Mbefo et al.
The Journal of biological chemistry, 290(15), 9412-9427 (2015-02-07)
Although α-synuclein (α-syn) phosphorylation has been considered as a hallmark of sporadic and familial Parkinson disease (PD), little is known about the effect of PD-linked mutations on α-syn phosphorylation. In this study, we investigated the effects of the A30P, E46K
Cristiane Latge et al.
The Journal of biological chemistry, 290(33), 20527-20540 (2015-07-08)
Cerebral dopamine neurotrophic factor (CDNF) is a promising therapeutic agent for Parkinson disease. As such, there has been great interest in studying its mode of action, which remains unknown. The three-dimensional crystal structure of the N terminus (residues 9-107) of

Número de artículo de comercio global

SKUGTIN
AB5336P04053252337574

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico